News articles about Akcea Therapeutics (NASDAQ:AKCA) have trended somewhat negative recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a daily sentiment score of -0.03 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.5074736318169 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- Akcea Therapeutics Inc. (AKCA) Is Suring After Teaming With Ionis – Nasdaq (nasdaq.com)
- Akcea Therapeutics (AKCA) Price Target Raised to $30.00 at Stifel Nicolaus (americanbankingnews.com)
- Akcea Announces Partnership with Ionis (financialbuzz.com)
- Hot healthcare stock to watch: Akcea Therapeutics Inc(NASDAQ: AKCA) (fxdailyreport.com)
- Why Akcea Therapeutics, Inc. Is Soaring While Ionis Pharmaceuticals Is Dropping (finance.yahoo.com)
Shares of Akcea Therapeutics stock opened at $31.21 on Monday. Akcea Therapeutics has a twelve month low of $8.10 and a twelve month high of $32.47.
WARNING: This report was first published by BBNS and is owned by of BBNS. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://baseballnewssource.com/2018/03/19/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-akcea-therapeutics-akca-share-price/2016832.html.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.